On September 30, Natera rose 3.05% in regular trading, trading at $426.74 per share, with turnover of approximately $196 million. The rally follows a series of bullish analyst upgrades and regulatory milestones.

RBC Capital Markets recently raised its price target on Natera significantly from $350 to $460 while maintaining an Outperform rating, highlighting that the company's next-generation ultra-sensitive molecular residual disease test, Signatera Genome, could emerge as the dominant clinical offering in the MRD space within a few years. UBS also previously lifted its target from $290 to $435 with a Buy rating, while Rothschild & Co Redburn initiated coverage at Buy with a $385 target, reflecting broad institutional optimism.

On the regulatory front, Japan's PMDA approved Signatera as a companion diagnostic for muscle-invasive bladder cancer, with commercial launch expected in the first half of next year. This follows an earlier PMDA clearance for colorectal cancer use. Additionally, Natera's Q2 results showed revenue of $752.8 million, beating estimates of $661.2 million, prompting the company to raise full-year revenue guidance to $2.85-$2.91 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)